Morgan Stanley maintains Fleetcor Technologies (NYSE:FLT) with a Equal-Weight and raises the price target from $275 to $285.
Sorrento Shares Pop After Interim Data From Lung Cancer Trial
Sorrento Therapeutics Inc (NASDAQ: SRNE) announced positive results from a pivotal study of Abivertinib on 209 response evaluable, heavily pretreated NSCLC patients by an IRC assessment with matured long-term follow-up data.
